Drug Profile
LAT 8881 -Lateral Pharma
Alternative Names: Advanced Obesity Drug 9604; AOD9604; LAT-8881; Tyr-hGH171191Latest Information Update: 14 Aug 2023
Price :
$50
*
At a glance
- Originator Monash University
- Developer Lateral Pharma Pty Ltd; Metabolic Pharmaceuticals
- Class Analgesics; Antimigraines; Peptide fragments; Peptide hormones
- Mechanism of Action Neuron inhibitors; Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Migraine; Neuropathic pain
- Phase I Pain
- No development reported Osteoporosis
- Discontinued Obesity
Most Recent Events
- 16 Jun 2023 Lateral Pharma completes a phase I trial for Pain (In adults) in Australia in (IV, infusion) (NCT05298306)
- 17 May 2022 Phase-I clinical trials in Pain (Radiculopathy lumbar) in Australia (IV) (NCT05298306)
- 28 Mar 2022 Lateral Pharma plans a phase I trial for Lumbar radicular pain (IV, infusion) in Australia in March 2022 (NCT05298306)